Financials data is unavailable for this security.
View more
Year on year Invex Therapeutics Ltd grew revenues 35.66% from 1.26m to 1.70m while net income improved from a loss of 7.75m to a smaller loss of 1.64m.
Gross margin | -- |
---|---|
Net profit margin | -96.35% |
Operating margin | -96.35% |
Return on assets | -11.35% |
---|---|
Return on equity | -12.20% |
Return on investment | -12.20% |
More ▼
Cash flow in AUDView more
In 2024, cash reserves at Invex Therapeutics Ltd fell by 16.45m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 2.44m. In addition the company used on investing activities and also paid 14.00m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0757 |
---|---|
Tangible book value per share | 0.0757 |
More ▼
Balance sheet in AUDView more
Current ratio | 14.18 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼